Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Gastrointestinal 1CNS 1

Conditions

Neoplasms 1Leukemia, Myeloid, Acute 1Glioma 1Cholangiocarcinoma 1

Interventions

Specimen Handling 321Magnetic Resonance Spectroscopy 276pembrolizumab 265Carboplatin 190Cyclophosphamide 184Biopsy 179Cisplatin 163Paclitaxel 137Gemcitabine 137Bevacizumab 124fludarabine 119Nivolumab 117Radiotherapy 114Oxaliplatin 92Docetaxel 90venetoclax 89Fluorouracil 88Capecitabine 88Dexamethasone 86Pemetrexed 75Drug Therapy 73Rituximab 72Leucovorin 71durvalumab 70Blood Specimen Collection 69Radiosurgery 68atezolizumab 67Standard of Care 67Doxorubicin 65Radiation 63

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Cytochrome P-450 CYP1A2 × 90 days × Clear all
NCT07486713 2026-06-05

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Rigel Pharmaceuticals

Phase 4 Recruiting
16 enrolled
CNSGastrointestinalOther hematologic neoplasm

Glioma, Neoplasms, Leukemia, Myeloid, Acute, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡